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Abstract
Human papillomavirus is a pathogen that directly infects cervical keratinocytes and may cause persistent infection 
that leads to cervical cancer. Toll like receptors (TLRs) play an essential role in initiating antiviral immune 
responses. Therefore, polymorphisms in TLR gene may contribute to cancer susceptibility. This study aimed 
to explore the TLR2 gene distribution and susceptibility to cervical cancer. In this case-control study, cervical 
cancer patients and their controls were recruited from the Department of Obstetrics and Gynecology, Dr. Hasan 
Sadikin General Hospital. Genomic DNA was extracted from blood of patients with histopathologically confirmed 
cervical cancer (n=100) and from unrelated, healthy female controls (n=100) during 2011. Three single nucleotide 
polymorphisms (SNPs) of the TLR2 gene were genotyped on the BeadXpress Reader system (Illumina)®. Chi 
square test was used to calculate the role of TLR2 and susceptibility to cervical cancer. Only subjects with complete 
clinical and genetic data were analyzed. Analysis of TLR2 rs3804099, rs4696480 and rs5743708 of cervical cancer 
patients and controls showed no significant association with the cervical cancer risk (p 0.424, p 0.275, p 0.209, 
respectively). Further classification in the FIGO (Fédération Internationale de Gynécologie et d’Obstétrique) 
criteria for lower stage (FIGO I/II) and higher stage (FIGO III/IV) showed a lack of association between TLR2 and 
cancer development, suggesting the possibility that TLR2 polymorphism does not play a role in the susceptibility to 
cervical cancer in this study. Other toll like receptors may be involved in the cancer susceptibility. The significance 
of TLR polymorphism should be further studied.  [MKB. 2013;45(4):257–62]
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Polimorfisme Gen TLR2 dan Perkembangan Kanker Serviks
Abstrak
Kanker serviks disebabkan oleh human papillomavirus (HPV), patogen yang dapat langsung menginfeksi 
keratinosit serviks secara persisten dan dapat berkembang menjadi kanker. Toll like receptors (TLR) berperan dalam 
merangsang respons imun, sehingga polimorfisme gen TLR dapat berkontribusi dalam kerentanan terhadap kanker. 
Tujuan penelitian ini adalah untuk mengetahui distribusi gen TLR2 dan peranannya terhadap kerentanan kanker 
serviks. Pada studi kasus kontrol, DNA genomik diekstraksi dari darah penderita kanker serviks yang terdiagnosis 
secara histopatologi (n=100) dan kontrol dengan Pap smear normal (n=100) tahun 2011 di Departemen Obstetri 
dan Ginekologi RSUP Dr. Hasan Sadikin Bandung. Pemeriksaan tiga single nucleotide polymorphisms (SNP) 
gen TLR2 dilakukan menggunakan BeadXpress Reader system (Illumina). Hanya subyek dengan data klinik dan 
genetik lengkap yang dianalisis dengan menggunakan uji chi square. Analisis dari TLR2 rs3804099, rs4696480 dan 
rs5743708 antara pasien dan kontrol tidak menunjukkan perbedaan yang bermakna (p 0.424, p 0.275 dan p 0.209). 
Di antara pasien dengan klasifikasi FIGO (Fédération Internationale de Gynécologie et d’Obstétrique) tingkat 
rendah (FIGO I/II) dan tingkat tinggi (FIGO III/IV) juga tidak tampak perbedaan yang bermakna. Dari penelitian 
ini terbukti polimorfisme TLR2 tidak berperan dalam proses kerentanan maupun perkembangan terjadinya kanker 
serviks. Kemungkinan TLR yang lain seperti TLR 1, 3, 9 lebih berperan dalam perkembangan terjadinya kanker 
serviks. [MKB. 2013;45(4):257–62]
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Methods
In this case-control study, peripheral blood samples 
were collected in Ethylenediaminetetraacetic acid 
(EDTA) tubes after informed consent  was gained 
from histopathologically confirmed squamous 
cervical carcinoma patients (n=100). As controls, 
unrelated, age-matched healthy female of similar 
ethnicity (n=100) who participated in Pap smear 
screening with no abnormalities were recruited 
from the outpatient clinic of the Department of 
Obstetrics and Gynecology, Dr. Hasan Sadikin 
General Hospital, Bandung Indonesia during the 
period of 2011. 
This study was a part of the Oncology 
Working Group research, and clearance of the 
protocol was granted by the Ethics Committee of 
the Faculty of Medicine Universitas Padjadjaran.
Genomic DNA was extracted according to the 
manufacturer's protocol (Qiagen, blood minikit, 
Germany) and was subjected to genotyping tests 
using BeadsXpressReader (Illumina®). Data 
on this system can be downloaded from http://
support.illumina.com/array/array_instruments/
beadxpress.ilmn). Using this genotyping 
system, 48 Single Nucleotide Polymorphisms 
(SNPs) were detected in total, with three TLR2 
SNPs were examined. These SNPs (rs3804099, 
rs4696480 and rs5743708) were taken from 
the literature reviews that are associated with 
cervical cancer development.
The chi-square test with a p-value of p<0.05 
was performed. To assess the risk for cervical 
cancer of each SNP, odds ratio (OR) and 95% 
confidence intervals (CI) were calculated. 
Results
Of all participants recruited only patients (n=71) 
and controls (n=38) with complete clinical 
records data were included in the study. The 
patients were staged according to the FIGO 
staging into stage I with 12 (16.9%) patients, 
stage II with 24 (33.5%) patients, stage III with 
34 (47.9%) patients, and stage IV with 1 (1.4%) 
patient (Table 1).
The mean age of the patients was 48.4 (± 
9.6) years old and the control group mean age 
was 45.6 (± 14.0) years old. Most of them 
were multiparous (2-4 pregnancies) and no 
significant difference was seen between patients 
and controls (66.2% and 68.4%, respectively). 
The clinical characteristics for age, parity and 
abortion of both groups showed no statistical 
significance in this study (Table 1). 
The distribution of the TLR2 polymorphism in 
cervical cancer patients for rs3804099 was shown 
Introduction
Cervical cancer is the second most common 
cancer in women worldwide with approximately 
500,000 new cases and 250,000 deaths each year.1 
In Indonesia, this cancer is considered the most 
frequent primary malignancy among women.2 
There is evidence that the immune system is of 
importance in the etiology of cervical cancer 
since human papillomaviruses (HPVs) are the 
main cause of the cancer.3 HPV directly infects 
cervical keratinocytes and interferes in the toll-
like receptor (TLR) signaling. Therefore, TLRs 
have been established to play an essential role 
in sensing and initiating the antiviral immune 
responses.4 The TLR signaling pathways have 
also been known to play roles not only in cancer, 
but also in several infections, inflammation, and 
autoimmune diseases.5 HPVs modulate TLR 
expression and interfere in the TLR signaling 
pathways which lead to persistent viral infection 
and carcinogenesis.6
There are 11 types of TLR with each type 
recognizes specific pathogens.7 A recent study 
in Northern India demonstrated that common 
nucleotide variations in TLR pathways may be 
associated with the risk of cervical cancer.8 This 
study showed that TLR expression in cervical 
cancer increases with HPV infection incidence. 
Nevertheless, there are no consistent associations 
between TLR gene polymorphism and infection 
risk.9 To shed light on the effect of HPV infection 
and the role of TLR2, we conducted this study in 
Bandung, West Java, Indonesia to compare TLR2 
gene polymorphim in cervical cancer patients and 
controls.
Figure 1 Distribution of TLR2 Gene rs3804099 as 
  shown in the GENOME STUDIO   
               program. Every dot is designated as one    
               individual to point the genotype TT, TC 
 or CC.
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in Figure 1. The result for genotype TT, TC and 
CC in patients were 43 (60.6%), 25 (35.2%) and 2 
(4.2%), respectively, and 20 (52.6%), 16 (42.1%) 
and 2 (5.3%) in control group, respectively. The 
TLR2 rs 3804099 genotype data in this study did 
not present any significant correlation (p=0.424). 
Further distribution of TLR2 polymorphisms is 
depicted in Table 2.
The TLR2 gene polymorphism distribution 
in cervical cancer patients was further classified 
according to the FIGO staging (Table 3). Stages 
were merged because of the low number of 
variables in each stage. Stage I-II were designated 
as lower stage in which tumor may extend through 
the upper 2/3 vaginal wall and parametria but 
does not reach the pelvic wall. Stage III-IV were 
designated as higher stage in which carcinoma 
has extended onto the pelvic wall and may extend 
beyond the true pelvis. The comparison between 
distribution of TLR2 genotypes in the lower stage 
and the higher stage is depicted in Table 3, that 
shows no significant difference between the two 
groups.
Discussion
The host immune system mechanism to prevent 
and control human papillomaviruses (HPVs) 
infection, which is the causative agent for the 
development of cervical cancer, remains poorly 
understood.10 The polymorphisms of the toll-like 
receptor gene is probably helpful to dissect the 
immunobiological mechanism that is associated 
with cervical cancer susceptibility because TLRs 
are specific pattern recognition molecules that 
bind to the virus components and trigger innate 
immunity and direct adaptive immunity.6
The cancer patients in our study were mostly 
multiparous with a mean age of mid forty. Results 
from a previous study has shown associations 
between HPV infection with high parity in 
developing cervical cancer.11 Multiparity may 
increase the risk for maintaining transformation 
zone in the ectocervical region of the cervix. 
There was also evidence on the increased number 
of squamous metaplasia during pregnancy.12 This 
could result in carcinogenic cellular growth in 
the transformation zone. Interestingly, HPV16 
infection is very common among young sexually 
active women. However, the majority of these 
women mount an effective immune response and 
may be able to clear the infection.13
Our study showed that the TLR2 gene was 
not associated with cervical cancer development. 
One may suggest that this different result might 
Table 1 Clinical Characteristic of Cervical Cancer Patients and Controls from  Dr. Hasan 
 Sadikin General Hospital year 2011
Patients (n=71)
n%
Control (n=38)
n%
p value
Age
Mean±SD (years) 48.4±9.06 45.6±14.0 0.198
Parity
Nulliparous 1 (1) 4 (11) 0.084
Primiparous (1 parity) 5 (7) 3 (88)
Multiparous (2-4 parity) 46 (65) 26 (68)
Grand Multiparous (≥5) 19 (27) 5 (13)
Abortion
No abortion 38 (54) 25(66) 0.469
Once 28 (39) 11(29)
Twice 3 (42) 2(5)
Thrice 2 (3) 0 (0)
FIGO stage *
I (%) 12 (17) -
II (%) 24 (34) -
III (%) 34 (48) -
IV (%) 1 (1) -
Note: * FIGO staging I, II, III and IV only in the cervical cancer patients
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be caused by diversities in the different types 
of TLR distribution in epithelia.6 For example, 
TLR2 is expressed on the cervical epithelium 
surface and also presents in active pouchitis and 
keratinocytes.14 TRL4, which is another type of 
TLR, was expressed on the pulmonary epithelium 
while TLR5 expressions are more prominent in 
the ileal mucosa.14
In cervical cancer development, infections 
caused by human papillomavirus is an essential 
factor in cervical carcinogenesis and cervical 
intraepithelial neoplasia (CIN) is a key stage in 
cervical cancer development that confirms chronic 
infection and inflammation as the most important 
factors contributing to cancer development and 
growth.10 Meanwhile, various TLR expressions in 
different stages of cervical cancer tissue had also 
been reported, showing that TLR2 expressions 
are more frequently found on cervical tissue 
epithelium.13 As the cervical cancer progresses, it 
Table 2 The Distribution of TLR2 Gene Polymorphism in Cervical Cancer Patients and Control 
 from Dr. Hasan Sadikin General Hospital year 2011
TLR2 Genotype
Patients
(n=71)
n (%)
Control
(n=38)
n (%)
p value OR
CI 95%
Lower Upper
rs3804099 TT 43 (61) 20 (53) Reff
TC 25 (35) 16 (42) 0.424 1.38 0.62 0.31
CC 3 (4) 2 (5)
rs4696480 TT 8 (11) 6 (19) Reff
TA 56 (79) 20 (65) 0.272 0.53 0.17 1.68
AA 7 (10) 5 (16)
rs5743708 AA 18 (25) 14 (37) Reff
AG 19 (27) 11 (29) 0.209 0.58 0.26 1.36
GG 34 (48) 13 (34)
Note: * pvalue < 0.05 set as significant  (x2 test). ** the wild type was designated as reference
Table 3 The Distribution of TLR2 Gene Polymorphism in Cervical Cancer Patients from Dr. 
 Hasan Sadikin General Hospital year 2011, Stratified by FIGO Classification
TLR2 Genotype
FIGO I/II
(n=36)
n (%)
FIGO III/IV
(n=35)
n (%)
p value OR
CI 95%
Lower Upper
rs3804099 TT 21 (58) 22 (63) Reff
TC 13 (36) 12 (34) 0.697 0.83 0.32 2.15
CC 2 (6) 1 (3)
rs4696480 TT 4 (11) 5 (14) Reff
TA 26 (72) 26 (74) 0.688 0.75 0.18 3.06
AA 6 (17) 4 (11)
rs5743708 AA 9 (25) 9 (26) Reff
AG 11 (31) 8 (23) 0.945 0.95 0.33 2.81
GG 16 (44) 18 (51)
Note: * pvalue < 0.05 set as significant (x2 test). ** the wild type was designated as reference
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penetrates to the deeper layer of the cervical lining. 
In higher FIGO stage, the tumor progression has 
breached the cervical epithelial layer. TLR 2 may 
not be capable to recognize the tumor anymore as 
it has already passed the epithelial layer. A similar 
study has also found that TLR polymorphism is 
associated with advanced stage of cancer which, 
in this case, is the higher FIGO stage.15
Evidence from a population in North India 
suggested that TLR2 genes played a significant 
role in cervical cancer development. However, 
TLR2 alone did not contribute to the susceptibility 
to cervical cancer.8 Study on TLR3 polymorphism 
showing association with the risk for developing 
cervical cancer was previously reported.15 There 
were various studies showing involvement of 
TLR4,16 TLR1, TLR3, TLR7, TLR8 and TLR917 in 
early and late cervical carcinogenesis suggesting 
that stromal up-regulation of TLRs plays a role 
in cervical disease progression.18 Interestingly, a 
recent study on TLR 9 gene polymorphism that 
is involved in the risk for developing cervical 
cancer15 was contradictive to the results of other 
groups showing that the promoter region of TLR9 
gene did not seem to have a mediating role in the 
natural history of the HPV infection.9
Data on TLR polymorphisms offer further 
insights regarding the association between HPV 
infection and TLR signaling during cervical 
cancer carcinogenesis. A  recent study also showed 
that the TLR up-regulation expression had been 
detected in many other tumor cell lines or tumors, 
especially in the epithelial derived cancer.17 In 
addition to TLRs, other genetic polymorphisms in 
the cytokines pathways might contribute to cancer 
development,19 including cytokine IFN, which is 
a key cytokine involved in the immunity.20 IFNG 
polymorphisms had previously shown significant 
correlation through an increase in higher stage 
(FIGO III/IV) cervical cancer.21 However, our 
previous study showed that IFNG is not a risk 
factor for cancer susceptibility.22
The limitation of this research was the small 
number of subjects with complete medical record 
data. Incomplete medical record data frequently 
becomes the problem in large clinical studies 
which might be due to patient’s failure in giving 
complete information or the physician's neglect 
in filling out data in the medical records. Better 
and complete medical record data are essential 
as one of the requirements in cancer registry 
for cancer control planning since it will be able 
provide various essential data regarding cancer 
incidence, mortality, and survival. Furthermore, 
low number of the research subjects might reduce 
the statistical power of the research. 
To conclude, TLR2 genotype in our study 
does not seem to show any significant correlation 
with cervical cancer susceptibility. As cervical 
epithelium contains diverse types of TLRs, other 
TLR genes need to be further explored since 
TLR is a promising target for the development of 
anticancer therapy. Future well-designed studies 
with a large sample size and complete clinical 
data should shed light on the significance of TLR 
polymorphisms for cancer prevention. 
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